Spermidine Alleviates Sepsis-Induced Acute Lung Injury through AMPK-Mediated Improvement of Necroptosis Authors: Bingqing Ye, Yuan Jin, Shansong Hu, Yiwei Shao, Qiaoyu Yang, Han Wu, Zhicheng Liu Published: 2025 ABSTRACT AbstractSepsis, a life-threatening organ dysfunction caused by dysregulated host responses to infection, often leads to sepsis-associated acute lung injury (SALI), a major contributor to mortality. Spermidine (SPD), a natural polyamine with anti-inflammatory and metabolic regulatory properties, has emerged as a potential nutritional adjunct for sepsis management. However, whether and how SPD ameliorates SALI remains to be elucidated. Here, cecal ligation and puncture (CLP) was performed in rats to simulate sepsis. Rat survival, lung injury score, Dry/Wet ratio, histopathology, cytokine levels and immunohistochemical analysis were analyzed to evaluate SPD’s effects on SALI. Targeted metabolomics, molecular docking and cellular thermal shift assay (CETSA) identified AMP-activated protein kinase (AMPK) as an underlying target of SPD’s action. In vitro investigations were based on lipopolysaccharide (LPS)-stimulated bone marrow-derived macrophages (BMDMs), with flow cytometry assessing apoptosis. AMPK inhibitor (Compound C) and downstream signaling were examined in vivo and in vitro through q-PCR and Western blot experiments. Consequently, SPD improved rat survival, reduced lung injury, and decreased pro-inflammatory cytokines in CLP rats. Metabolomics, molecular docking and CETSA suggested AMPK-mediated energy metabolism modulation. Mechanistically, SPD attenuated necroptosis via AMPK/RIPK1/MLKL signaling. Moreover, Compound C counteracted the protective effect of SPD on SALI in vivo and in vitro. Our findings evidence that SPD significantly ameliorates SALI via the regulation of AMPK-mediated necroptosis. SPD supplementation may serve as a complementary therapeutic approach, warranting further investigation in subsequent clinical trials for sepsis treatment.Supplementary InformationThe online version contains supplementary material available at 10.1007/s10753-025-02372-8.Keywords: Sepsis, Spermidine, SALI, Metabolomics, AMPK, Necroptosis Introduction Sepsis is life-threatening condition characterized by dysregulated host responses to infection, resulting in systemic inflammation and multi-organ dysfunction [1]. With an incidence rate estimated at 50–100 cases per 1000 hospital admissions, sepsis represents a major global health challenge associated with substantial mortality and significant healthcare burdens [2]. Among its severe complications, sepsis-induced acute lung injury (SALI) is one of the most common and lethal complications, serving as a major contributing factor to patient mortality. SALI, characterized by uncontrolled systemic inflammation, endothelial dysfunction, and alveolar damage [3]. Due to the complicated mechanism of the development of SALI remains unclear, options are limited and lack of specificity for the treatment of SALI until present. Septic progression leads to comprehensive metabolic reprogramming, with particularly prominent disruptions in energy metabolism pathways. Substantial evidence has revealed dysregulation of multiple enzymes governing glycolytic and tricarboxylic acid (TCA) cycle intermediate metabolism in septic conditions [4]. These metabolic disturbances are principally associated with disturbed inflammatory responses-driven insulin resistance and chaos of anaplerotic reactions in amino acids. As a consequence, the deprivation of energy supply further inhibits immune cells’ ability to clear infection-associated pathogen/damage-associated molecular patterns and ultimately aggravate injuries in the organs. Our recent findings further demonstrate that SALI could be alleviated by enhanced nicotinamide adenine dinucleotide (NAD+) biosynthesis [5]. Hence, therapeutic strategies targeting metabolic homeostasis restoration have emerged as a promising approach for mitigating sepsis-induced organ dysfunction. Spermidine (SPD), an essential endogenous polyamine, is not only widely present in various foods including soybeans, wheat germ and fermented products, but also a crucial inherent polyamine metabolite in mammals [6]. As a caloric restriction mimetic, SPD enhances autophagy [7]—a cellular recycling process critical for maintaining homeostasis, and has been linked to lifespan extension, cardiovascular health improvement, and mitigation of age-related diseases [8]. Experimental evidence demonstrates that SPD intervention inhibits inflammatory dendritic cell (DC) activation through FOXO3-dependent mechanisms, thereby mitigating autoimmune pathogenesis [9]. Emerging evidence reveals significant dysregulations of endogenous polyamine metabolism during sepsis [10], which have consistently demonstrated markedly decreased SPD in the circulation and multiple organs during sepsis. Given the particular susceptibility of pulmonary tissue to hypoxic and inflammatory insults during sepsis, SPD presents a compelling therapeutic candidate due to its multimodal actions encompassing anti-inflammatory, antioxidant, and organ-protective properties - all of which directly target the pathophysiological features of SALI. Previous studies have shown that arginine supplementation enhances protein synthesis while attenuating excessive catabolic activity in septic conditions [11, 12]. Similar effects were also observed in spermine [6]. Such findings involving polyamine metabolites establish SPD as a promising therapeutic candidate for the complementary treatment on SALI. Previous findings indicate that metabolic dysregulation is closely associated with aberrant programmed cell death (PCD), including ferroptosis triggered by excessive lipid peroxidation. Similarly, overactivated necroptosis, known as one kind of necrotic PCD, is also observed to be parallel with mitochondrial injuries and energy deficiency [13–15]. An inhibition of receptor-interacting protein kinase 1 (RIPK1)-induced necroptosis has been proved to ameliorate acute liver failure, as reported by Kondo et al. [16]. SPD has been shown to downregulate RIPK1 expression [17], prompting our hypothesis that SPD intervention might confer therapeutic benefits in SALI by improvements of necroptosis. Interestingly, other studies suggest that dysregulated energy metabolism may contribute to necroptosis [18], Nevertheless, whether SPD’s effect on SALI is associated with an improvement of energy metabolism disorders-related necroptosis remains to be elucidated. To this end, the current study aims to explore the energy metabolism-regulated and anti-necroptosis effects of spermidine on SALI in rats with CLP modeling and in LPS-stimulated cells. This study bridges SPD’s established bioactivities with its unexplored role in SALI, advancing the evidence for energy metabolism interventions in sepsis treatment. By combining preclinical models with mechanistic insights, it may provide a translational foundation for the complementary therapy in SALI. Materials and Methods Reagents SPD and dexamethasone (DEX) were sourced from YuanYe Biosciences Ltd (YuanYe, Shanghai, China), and Compound C (CC) was procured from MedChem Express (MCE, CA, USA). Antibodies utilized in immunoblotting analyses, specifically those targeting total AMPK, RIPK1 and β-actin, were obtained from Affinity Biosciences Ltd (Affinity, JiangSu, China). Antibody against MLKL was sourced from Proteintech (Proteintech Group, Wuhan, China). The antibody for p-AMPK(Thr172) was purchased from Cell Signaling Technology (Danvers, MA, USA), and those against p-RIPK1 (Tyr384) and p-MLKL(Ser358) were purchased from Affinity Biosciences Ltd (Affinity, JiangSu, China). Lipopolysaccharide (LPS) was purchased from Merckgroup (Sigma, Germany). The standard references of the glycolysis and TCA intermediates, as well as two internal standards were all bought from Sigma-Aldrich (St. Louis, MO, USA). Animal Experiments and Samplings Four batches of rats were included in the study. For the first batch, 48 specific pathogen free (SPF)-grade Sprague-Dawley (SD) rats (220–240 g, male) were supplied by Beijing Hua Fu Kang Biotechnology Ltd (Beijing, China). The rats were fed commonly with stable ambient temperature and illumination for 7 days. The rats were then given prophylactic interventions for 7 days and randomly divided into four groups (n = 12/group): the SPD group was given spermidine (10 mg/kg) by gavage daily in the 7 days, the DEX group received dexamethasone (10 mg/kg) by gavage daily, the Sham group and Model group were given an equal volume of double-distilled water at the same time. LPS was administered intraperitoneally to each rat at a dose of 10 mg/kg. Briefly, rats were anesthetized with sodium pentobarbital (30 mg/kg) by intraperitoneal injection. Their cecum was exposed and ligated by 7.5 mm to its end. The ligated cecum was punctured (≈ 1.5 mm) with a sterile 21-gauge needle. The Sham group only received cecum exposure without ligation or puncture; the others were resuscitated by sterile 0.9% saline. This batch was preserved for the observation of SPD’s effect on the survival of sepsis-mimicked rats by a survival curve and the rat survival was monitored for 3 days after modeling operation. For the second batch of animals, 36 SPF-grade SD rats were obtained from the same company as the previous animal experiment. The rats were randomly divided into four group as same as the first batch (n = 6 for the Sham group while n = 10/group for the other groups), and all operations were consistent. 24 h post-CLP modeling, surviving animals (Sham:6, Model:7, SPD:8, DEX:6) were euthanized for sample collection. Blood was obtained via abdominal aortic puncture and centrifuged (3000 rpm, 15 min, 4 °C) to isolate serum. Lung tissues and bronchoalveolar lavage fluid (BALF) were collected, flash-frozen in liquid nitrogen, and stored at −80 °C for subsequent analysis. The purpose of this batch was to obtain lung tissue samples and BALF for the later experiments. For the third batch of animals, 42 SPF-grade SD rats (220–240 g, male) were obtained from the same company as the previous batches. The rats were randomly divided into three groups (n = 14/group). Of the animals, one group was treated only with AMPK-inhibitor, Compound C (10 mg/kg) by gavage daily in 7 days (the CC group), and the others were meanwhile treated with both CC and SPD (the SPD + CC group, with the doses at 10 mg/kg for both compounds) or an equal dose of SPD (the SPD group, 10 mg/kg). CLP surgery was performed in all rats, this batch of the rats was divided into two parts: one part was remained 8 rats in each group for the survival curve (n = 8/group, for a total of 24 rats) after CLP surgery immediately; the other part was anesthetized and sampled 24 h after CLP surgery, and rats remained alive including 5 rats in the SPD group, 3 rats in the CC group, 4 rats in the SPD + CC group. The lung tissue and BAFL samples of these rats were collected as described above. The finally batch of animals was utilized to validate the consistency of SPD’s mechanism between different sepsis models. 40 SPF-grade SD rats were randomly divided into two distinct modeling approaches. For the CLP modeling approach, 24 rats were divided into four groups (n = 4 for the Sham group, n = 9 for the Model group while n = 6/group for the other groups) and subjected to CLP surgery. Surviving animals 24 h post-modeling (Sham:4, Model:3, SPD:4, DEX:3) were euthanized for lung tissue collection for immunohistochemical analysis. For the LPS modeling approach, 15 SPF-grade SD rats were obtained from the same company as the previous animal experiment. The rats were randomly divided into two groups (n = 9 for the Model group while n = 6 for the LPS + SPD group): the LPS group and LPS + SPD group, the LPS + SPD group was given spermidine (10 mg/kg) by gavage daily in the 7 days, the LPS group were given an equal volume of double-distilled water at the same time. At 24 h post-LPS injection (10 mg/kg), lung tissue of surviving rats (LPS:3, LPS + SPD:4) was harvested. Lung tissues from both the CLP and LPS-induced rat models were subjected to immunohistochemical analysis of p-AMPK, p-RIPK1, and p-MLKL expression, confirming SPD’s conserved regulatory effect on this pathway across modeling methodologies. All the procedures of animal experiments were approved by the Animal Care Committee of Anhui Medical University (LLSC20240853). Preparation of Bone Marrow-Derived Macrophages and Cell Culture Primary bone marrow-derived macrophages (BMDM) were extracted from normally fed rats without any interventional operation. The extracted bone marrow cells were then cultured in DMEM medium (Yuan Pei, Shanghai, China) supplemented with 20 ng/ml M-CSF (Novo protein, Su Zhou, China) and 10% fetal bovine serum (FBS, WISENT, Nan Jing, China). The medium was partially refreshed with bone marrow macrophage induction medium on the third day and completely replaced on the fifth day. On the 7th day of cell culture, the cells were ready for the following experimental procedures. Cell Counting Kit-8 (CCK-8) Assay All procedures were performed in strict accordance with the manufacturer’s instructions (GlpBio Technology, Montclair, CA, USA). BMDM Cell Treatments BMDM cells were stimulated with LPS (10 µg/ml). Among the groups, three were treated with varying concentrations of SPD (10 µM, 20 µM, and 40 µM) after LPS stimulation for four hours as the previous research [19]. Besides, we treated the BMDM cells with Compound C (10 µM) for 30 min before SPD supplementation (40 µM). Metabolomics Analyses BALF samples were thawed at 4 °C. To 100 µL of each BALF sample, 400 µL of methanol solution (methanol: water = 4:1 with internal standard succinate-d6 and ATP-15N5-13C10 both at 1 µg/mL) was added to extract the metabolites. The samples were then vortexed for 2 min, and centrifuged at 4 °C, and 15,000 rpm for 15 minutes. The supernatant (100 µL) was lyophilized, re-solubilized with 100 µL of mobile phase, and transferred to a 2 mL glass vial, which was stored at 4 °C until analysis. A liquid chromatography coupled with mass spectrometry platform (ABSciex 5500, Danaher, USA) was used for the metabolomic analysis. The column was maintained at 40 °C with the flow rate of 0.35 mL/min and injection volume of 2 µL. The mobile phase gradient is detailed in Table 1. Table 1Mobile phase gradientStepTotal time (min)Eluent A (vol%)Eluent B (vol%)10–1.2.259528307039–115050411.1–15595 Mobile phase gradient Mass spectrometry was conducted at an electrospray ionization source (ESI), with mass spectrometry voltages set at 5500 V for the positive ion mode and − 4500 V for the negative ion mode. The curtain gas pressure was at 35 psi. Energetic metabolism-associated metabolites were targeted in the analyses according to the protocol developed by Roberts et al. [20]. All the ions were detected by the negative mode with multiple mode reaction monitoring (MRM). The de-clustering potential (DP), collision energy (CE) of the targeted precursor (Q1)-product (Q3) ion pairs was optimized before data acquisition, as shown with their linear regression equation for their quantification, in Table S-1. Data acquisition and evaluation were performed using Analyst software (version 1.7, AB Sciex LLC, MA, USA). Wet/Dry Weight Ratio of Lung Tissues The wet/dry weight ratio (W/D) is an indicator of pulmonary edema severity in rats. The wet weight of rat lung tissues was recorded after gently wiping the surface blood. The tissues were then dried and weighed to obtain the dry weight. Pathological Examination of Lung Tissues The lung injury scores of rats were recorded based on the degree of neutrophil infiltration, alveolar and interstitial edema, and the degree of pulmonary tissue hemorrhage. Specifically, the scores ranged from 0 to 4: 0, normal lung; 1, mild lung injury (less than 25% injury); 2, moderate lung injury (25%−50% injury); 3, wide lung injury (50%−75% injury); and 4, extreme lung injury (more than 75% injury). Besides, rat lung sections were fixed in 4% paraformaldehyde and embedded in paraffin for subsequent processing. Hematoxylin and eosin(H&E) staining was performed to visualize the tissue, and micrographs were taken by using slide scanning system (3D HISTECH, Pannoramic scan, Hungary). Immunohistochemical (IHC) Analysis Tissue sections were deparaffinized, rehydrated, and treated with 3% H2O2 for 30 min. Subsequently, the sections were blocked with normal goat serum. Primary antibodies against p-AMPK (dilution: 1:200), p-RIPK1 (dilution: 1:50) and p-MLKL (dilution: 1:50) were applied overnight at 4 ◦C. After washing, the sections were incubated with biotinylated secondary antibodies, developed, and visualized under a microscope. Immunostaining results were quantitatively analyzed using ImageJ software (version 1.54d). Enzyme-Linked Immunosorbent Assay (ELISA) BALF concentrations of IL-1β, IL-6 and TNF-α were assessed by ELISA kits (Dakewe Biotech Co., Ltd, ShenZhen, China) according to the manufacturer’s protocols. Protein Molecular Docking Molecular Operating Environment 2022 (CCGI, Moe, Canada) software was employed for molecular docking between AMPK and SPD. The molecular structure of spermidine was retrieved from the PubChem database, and the three-dimensional coordinates of the protein AMPK (PDB ID, 2QRC; resolution, 2.70 Å) were sourced from the Protein Data Bank(https://www.wwpdb.org/). Cellular Thermal Shift Assay (CETSA) The BMDM cells were divided into two groups: the control (PBS) group and SPD group, with the cells co-incubated with 40 µM of SPD. The control group received an equal volume of PBS. After 3 h of incubation, cells were harvested and subsequently divided into five aliquots. The cell suspensions were equally distributed into five 1.5 ml centrifuge tubes and subjected to different temperature conditions (40 °C, 45 °C, 50 °C, 55 °C and 60 °C). Following 5 min of heat treatment, the samples were immediately placed on ice. After returning to room temperature, the cells were centrifuged at 1,200 rpm for 5 min at 4 °C. The supernatant was removed, and proteins were extracted from the cell pellets for subsequent Western Blot analysis. Quantitative Real-Time PCR(q-PCR) Total cells or tissues RNA was extracted with TRIZOL Reagent (Thermo Fisher Scientific, USA) according to the manufacturer’s instructions, the cDNA was synthesized by using the first strand cDNA synthesis kit (Takara Shuzo, Kyoto, Japan). q-PCR was applied using the SYBR Green dye (Takara, Japan) on LightCycler 480 system (Roche, Penzberg, Germany). The primer sequences used in this study were listed in Table 2. The relative expression was normalized to β-actin by 2-ΔΔCt method. Table 2Q-PCR primer sequencesGeneOrganismprimer sequenceAMPKRattusF:5’-AATTCGCAGGGAGATTCAGA-3’R:5’-ACAGCTCTCCTCCAGAAACG-3’RIPK1RattusF:5′-TCCTCGTTGACCGTGAC-3′R:5′-GCCTCCCTCTGCTTGTT-3′MLKLRattusF:5’-AGACTTCTATAAGCCGGGCAAC-3’R:5’-TCACAGCCTTCAAACGGGAT-3’ Q-PCR primer sequences F:5’-AATTCGCAGGGAGATTCAGA-3’ R:5’-ACAGCTCTCCTCCAGAAACG-3’ F:5′-TCCTCGTTGACCGTGAC-3′ R:5′-GCCTCCCTCTGCTTGTT-3′ F:5’-AGACTTCTATAAGCCGGGCAAC-3’ R:5’-TCACAGCCTTCAAACGGGAT-3’ Western Blotting Lungs or BMDM cells were lysed in RIPA buffer. Total protein concentrations were determined using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, USA). Proteins were resolved on SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) gels and transferred to PVDF membranes via wet transfer. The membranes were blocked in TBST buffer containing 5% skimmed milk powder for 1 h before probing with primary antibodies. The information of the primary antibodies used in this study were listed in Table 3. Images were acquired using HRP-coupled secondary antibodies (Proteintech Group, Wuhan, China), and optical density was measured using BioRad ChemiDox (BioRad Laboratories, CA, USA). Table 3The antibodies used in the studyAntibodySourceDilutionsCompanyβ-actinRabbit1:5000Affinity, JiangSu, ChinaAMPKRabbit1:1000Affinity, JiangSu, ChinaRIPK1Rabbit1:1000Affinity, JiangSu, ChinaMLKLRabbit1:2000Proteintech, Wuhan, Chinap-AMPKRabbit1:1000Cell Signaling Technology, MA, USAp-RIPK1Rabbit1:1000Affinity, JiangSu, China The antibodies used in the study Flow Cytometry Detection of Cell Apoptosis V-FITC/PI Apoptosis kit (Elabscience, WuHan, China) was used for a flow cytometry (Beckman, MoFlo XDP, USA) to observe apoptosis in BMDM cells. All steps were carried out according to the manufacturer’s instructions. Acquired data were analyzed by flow cytometry using a MoFlo XDP instrument (Beckman, USA) and FlowJo software (Tree Star, Ashland, OR, USA). Statistical Analysis The normalized data exhibited in the column or box charts were presented as mean ± standard deviation (SD) for each group, calculated from at least three independent experiments. Statistical analysis was conducted using GraphPad Prism 9.5 (GraphPad Software, San Diego, USA). Multiple group comparisons were analyzed by one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test and p-value of < 0.05 was considered to be statistically significant. Results Spermidine Improved Survival and SALI in Septic Rats The CLP modeling was applied to mimic sepsis in rats. To explore the effect of SPD against SALI, the survival and stained tissue section after modeling operations were observed in the groups of rats. DEX, a previously used drug for clinical treatment of sepsis-associated inflammation, was applied as the positive control group. According to the survival curve, SPD and DEX were both shown to raise the survival rate during three days after modeling operations (Fig. 1A), but SPD showed a slightly better survival rate compared with DEX. As shown in Fig. 1B, CLP operations resulted in significant infiltration and death of inflammatory cells in rat lung tissue, which were alleviated by the supplementation of spermidine. The protective effect of SPD against SALI was also evidenced by decreased lung tissue damage scores and W/D ratio in the SPD group, compared to the Model group (Fig. 1C-D). Such results demonstrated that spermidine was able to improve the survival and SALI in CLP rats. Spermidine improved the survival and SALI in CLP rats. (A) Survival curve (n = 12). (B) Representative images of lung sections with H&E staining (20 X), and the scale bars represented 50 µm. (C) Tissue damage score of lungs. (D) Lung W/D weight ratio. (E-F) BALF levels of IL −1β, TNF -α and IL −6. Data were presented as mean ± SD (n = 3). Compared with the Model group, *P < 0.05, **P < 0.01, ***P < 0.001 Moreover, the CLP surgery was also characterized by an increase of the pro-inflammatory cytokines IL-6, TNF-α and IL-1β. Accordingly, after the administration of SPD, the levels of IL-6, TNF-α and IL-1β were significantly reduced in BALF. Such effects were similar to those in the BALF of CLP rats treated with DEX (Fig. 1E-G). Spermidine-Mediated Modulations in Glycolysis and TCA Intermediates were Associated with its Effect on AMPK Energy deficiency is a major contributor of sepsis-induced organ failure. Increasing evidence have indicated that targeting the energy metabolism is a promising therapeutic strategy for mitigating sepsis-associated organ dysfunction. Glycolysis and TCA intermediates are core targets affected in sepsis-induced metabolic dysfunction. To investigate whether and how SPD affected the energy metabolism, we conducted targeted metabolomic analysis in the alveolar lavage fluid of rats to determine whether SPD’s protective effect against SALI was associated with its regulation on glycolysis or TCA intermediate metabolites [21]. The results revealed four energy-related metabolites exhibiting significant inter-group differences: phosphoenolpyruvate (PEP), citrate (CIT), 2-oxoglutarate (α-KG), and fumarate (FUM). Notably, PEP, the terminal glycolytic metabolite, was significantly downregulated in the Model group but restored by SPD group. Parallel effects were also observed in TCA cycle intermediates α-KG and FUM, and CIT (Fig. 2A). These findings confirmed that SPD modulated both glycolytic and the TCA cycle in the BALF of CLP rats. Intriguingly, DEX, a known AMPK activator, produced comparable metabolic effects to SPD treatment [22]. Spermidine modulated TCA metabolism in BALF of CLP rats by regulating AMPK. (A) Schematic diagram of differential metabolites in glycolysis and TCA cycle. (B) Three-dimension (3D) structural diagram of AMPK protein. (C) An overall view of 3D molecular docking between SPD with AMPK protein. (D) 3D Local diagram of molecular docking between SPD with AMPK protein. (E) 2D representative diagram of docking between AMPK and SPD. (F) q-PCR determination of mRNA expression of genes involved in ampk in rat lung tissues. Data were presented as mean ± SD (n = 3). Compared with the Model group, *P < 0.05, **P < 0.01, ***P < 0.001. (G) Representative Western blot results and its quantitative analysis showing the levels of soluble AMPK and β-actin at the indicated temperatures in CETSA. Data were presented as mean ± SD (n = 3). Compared with the PBS group, ‘ns’ represented no significance, *P < 0.05 AMPK, a crucial energy-sensing kinase, monitors cellular energy status and directly phosphorylates key regulatory factors across multiple metabolic pathways during energy stress, targeting glucose transporter to stimulate glucose utilization and restore energy homeostasis. Importantly, AMPK activation promotes glycolysis and optimizes TCA cycle function to maintain energy balance during critical illness with energy deprivation [23]. Since our findings showed SPD-mediated modulations in one glycolysis metabolite, PEP, and three TCA cycle intermediates (CIT, α-KG, and FUM), we hypothesized that AMPK was an underlying target of SPD’s effect on SALI. To assess whether SPD has the potential to directly bind to AMPK, we performed a molecular docking analysis. Using Moe 2022, we obtained information on the binding sites and interactions of SPD with AMPK proteins (Fig. 2B-E). Our results indicated that spermidine formed a stable binding to the target protein through visible hydrogen bonding. The calculated affinity energy was at −5.0178 kcal/mol between SPD and AMPK, showing a stable affinity between the two molecules (Fig. 2D). At the mRNA level, ampk was decreased in the Model group, while both SPD and DEX treatments could significantly restore its level (Fig. 2E). Consistent with this, the results of CETSA revealed that SPD notably enhanced the thermal stability of AMPK protein, with the highest level observed at 50 °C (Fig. 2G), demonstrating a direct interaction between SPD and AMPK. Taking together, these findings suggest that spermidine modulates metabolites associated with glycolysis and the TCA cycle through AMPK activation—a mechanism previously shown to ameliorate lung injury [24]. Spermidine Suppressed Necroptosis Via AMPK/RIPK1/MLKL Pathway in LPS-Induced BMDM Cells To elucidate the mechanism whereby SPD protects against SALI by attenuating energy metabolism-associated necroptosis, we subsequently investigated the role of AMPK and its related effector proteins involved in necroptosis in vitro. As shown in Fig. S-1, the results of CCK8 indicated the low toxicity of SPD in BMDM cells (IC50 = 79.54 µM). A flow cytometry analysis was conducted to observe the apoptosis rate of BMDM cells. As depicted in Fig. 3A, the flow cytometry assay confirmed that LPS stimulation induced late apoptosis/necrosis in BMDM cells, which was generally reversed by the treatments of different dosages of SPD (10 µM, 20 µM, and 40 µM). Notably, as evidenced previously, SPD showed inhibitory effects on RIPK1. In addition, studies by Zhang T et al. [25]– [26] have demonstrated that elevated SPD concentrations exhibit a negative correlation with RIPK1 phosphorylation levels, indicating that SPD may suppress RIPK1 phosphorylation. Interestingly, it has been shown that inhibiting AMPK phosphorylation leads to increased RIPK1/MLKL phosphorylation [27], which may exacerbate pulmonary edema, inflammatory infiltration, and tissue damage. Therefore, we speculated that that SPD attenuates this pathogenic cascade through AMPK-dependent suppression of RIPK1/MLKL-associated necroptosis. To demonstrate the above speculations, mRNA expressions of the involved genes were investigated. Consequently, mRNA expressions of necrotic apoptosis-involved proteins (ripk1 and mlkl) were significantly increased in BMDM cells, while ampk level was significantly decreased after LPS stimulation (Fig. 3B-D). In contrast, SPD reversed these changes. Similar variations of the targeted protein expressions were observed in Fig. 3E-H: in particular, compared to the LPS group, SPD treatment induced dose-dependent reductions in the phosphorylation ratios of necroptosis-related proteins (p-RIPK1/RIPK1 and p-MLKL/MLKL), while significantly increasing the p-AMPK/AMPK ratio in a dose-dependent manner. Spermidine suppressed necroptosis via AMPK/RIPK1/MLKL pathway in LPS-induced BMDM cells. (A) Flow cytometry diagram of BMDM cells. ‘Q1’ represented dead cells, ‘Q2’ represented late apoptosis or necrosis, ‘Q3’ represented early apoptosis, ‘Q4’ represented viable cells. (B-D) q-PCR determination of mRNA expressions of the genes ampk, ripk1 and mlkl in BMDM cells, respectively. (E) Representative images of Western blot results of RIPK1, MLKL, p- RIPK1, p-MLKL and β-actin in BMDM cells. (F-H) Protein relative expression ratio of p-AMPK/AMPK, p-RIPK1/RIPK1 and p-MLKL/MLKL in BMDM cells. Data were presented as mean ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, ‘ns’ represented no significance, compared with the LPS group. (I) Representative images of Western blot results of RIPK1, AMPK, MLKL, p- RIPK1, p-AMPK, p-MLKL and β-actin in in BMDM cells. (J-L) Protein relative expression ratio of p-AMPK/AMPK, p-RIPK1/RIPK1 and p-MLKL/MLKL in BMDM cells. Data were presented as mean ± SD (n = 3). Compared with the LPS + CC group, ‘ns’ represented no significance, *P < 0.05, **P < 0.01, ***P < 0.001 To further explore whether the anti-necroptosis effect of SPD on BMDM cells was via the AMPK/RIPK1/MLKL pathway, the AMPK inhibitor-Compound C, which also suppresses AMPK phosphorylation, was subject to BMDM cells to observe expression variations in the targeted proteins [28]. Consequently, the intervention of Compound C significantly reversed the protective effect of SPD (40 µM) (Fig. 3I-L). To summarize, these results revealed that spermidine improved LPS-induced necroptosis via AMPK/RIPK1/MLKL signaling in vitro. Spermidine Alleviated SALI by Regulating AMPK/RIPK1/MLKL Pathway in CLP Rats Based on cellular experimental findings, we hypothesized that spermidine alleviates SALI by activating AMPK and subsequently modulating the RIPK1/MLKL-mediated necroptosis pathway. To further verify whether SPD exerts its protective effect against SALI through the same mechanism in vivo, we examined the expression of key targets related to SPD in lung tissues from another batch of CLP rats. Beyond the ampk expression patterns across groups previously determined in Fig. 2F, the mRNA levels of ripk1 and mlkl were significantly elevated in the Model group (Fig. 4A–B). These changes were partially reversed by DEX but consistently reversed by the supplementation of SPD, respectively. Spermidine alleviated SALI by regulating AMPK/RIPK1/MLKL pathway in CLP rats. (A-B) q-PCR determination of mRNA expression of genes involved in ripk1 and mlkl respectively in rat lung tissues. (C) Representative images of Western blot results of RIPK1, AMPK, MLKL, p- RIPK1, p-AMPK, p-MLKL and β-actin in rat lung tissues. (D-F) Protein relative expression ratio of p-AMPK/AMPK, p-RIPK1/RIPK1 and p-MLKL/MLKL in rat lung tissues. (G) Immunohistochemical images showing the expression of p-AMPK, p-RIPK1 and p-MLKL in lung tissues. (H-J) Immunohistochemical analysis of p-AMPK, p-RIPK1 and p-MLKL expression in lung tissues. Data were presented as mean ± SD (n = 3). Compared with the Model group, ‘ns’ represented no significance, *P < 0.05, **P < 0.01, ***P < 0.001 To confirm the generalizability of regulations in the focused pathway between different methods of modeling, we also performed immunohistochemical analysis in another LPS-stimulated sepsis-like rats, assessing p-AMPK, p-RIPK1, and p-MLKL levels in LPS and LPS + SPD groups (Figure S-2). The results indicated that SPD similarly regulated the AMPK/RIPK1/MLKL pathway in the LPS model, as evidenced by significantly increased levels of p-AMPK and decreased expression of p-RIPK1 and p-MLKL in lung tissues. Such findings suggest consistent effects of SPD against SALI are common in different sepsis-like animal models. However, as the CLP model mimicking multiple origins of infections is more clinically representative and widely adopted in sepsis research [29], we focused subsequent mechanistic validation on this system. At the protein level, Western blot analysis confirmed that the expression ratios of p-RIPK1/RIPK1 and p-MLKL/MLKL were upregulated, while the p-AMPK/AMPK expression ratio was down-regulated in the Model group (Fig. 4C–F). These findings were further corroborated by immunohistochemical data from CLP rat lung tissues, which demonstrated consistent alterations in the phosphorylation status of these proteins (Fig. 4G–J). As anticipated, SPD treatment reversed these changes, aligning with both the mRNA expressions and previous in vitro observations. The counteracting effect of Compound C against SPD on SALI was also validated in CLP rats to confirm the role of AMPK-associated regulations on necroptosis in SALI. According to the survival curve, SPD and SPD + CC group were both shown to raise the survival rate during three days after modeling operations (Fig. 5A), and CC groups showed the lowest survival rate in three groups. As shown in Fig. 5B, among the groups of CLP rats, the CC group showed an aggravated infiltration of inflammatory cells, indicating worsened inflammation and damage in the lung tissue. The administration of SPD significantly improved lung injury, which was consistent with previous results. However, the intervention of Compound C (SPD + CC group) partially counteracted the effect of SPD. Consequently, Compound C partially counteracted the effect of SPD on AMPK mediated necrosis pathway: we found that Compound C significantly decreased the expression ratio of p-AMPK/AMPK and increased the protein ratios of p-RIPK1/RIPK1 and p-MLKL/MLKL (Fig. 5C-E). Together, as expected, these data evidenced that spermidine improved SALI through AMPK-dependent improvement of necroptosis in vivo. The counteracting effect of Compound C on SALI against spermidine was regulated via AMPK-associated necroptosis pathway in CLP rats. (A) Survival curve (n = 8) (B) Representative images of lung sections with H&E staining (20 X), and the scale bars represented 50 µm. (C) Representative images of Western blot results of RIPK1, AMPK, MLKL, p- RIPK1, p-AMPK, p-MLKL and β-actin in in rat lung tissues. (D-F) Protein relative expression ratio of p-AMPK/AMPK, p-RIPK1/RIPK1 and p-MLKL/MLKL in rat lung tissues. Data were presented as mean ± SD (n = 3). Compared with the CC group, *P < 0.05, **P < 0.01, ***P < 0.001 Discussion SALI presents particular therapeutic challenges due to its complex pathophysiology. Despite therapeutic advances in sepsis management, SALI remains a significant clinical challenge [30]. Emerging evidence derived from animal and human studies indicates that SPD may prevent various inflammation-related cardiovascular/neurological disorders and intestinal dysfunction [31]. SPD is also known to ameliorate hepatic steatosis in rodents [32], primarily through anti-inflammatory, autophagy regulation antioxidant, and anti-apoptotic mechanisms. Here, our study demonstrates that SPD protects against sepsis-induced organ damage by regulating AMPK mediated necroptotic pathway. Our findings highlight SPD’s potential as a complementary therapeutic approach for SALI. Sepsis induces profound metabolic reprogramming across all cell types, extending beyond well-characterized immune cell alterations to include nutrient competition and microenvironmental stress [33]. While immune cell-centric metabolic changes have been well characterized, growing evidence reveals that metabolic stress critically regulates immune responses. For instance, glucose deprivation coupled with lactate accumulation has been demonstrated to compromise the cytotoxic capacity of T cells and natural killer (NK) cells while promoting immunosuppressive M2 macrophage polarization [34]. Furthermore, recent studies have shown that amino acids (leucine, glutamine, glutamate) directly modulate B cell function in tumor microenvironments [35]. Considering the substantial presence of immune cell-derived cellular debris in BALF, we systematically analyzed the dynamic changes in glycolytic and TCA cycle metabolites, which may directly reflect the dysregulated enzymes responsible for energy metabolism in the lungs. Our findings show that sepsis significantly disrupts glycolytic-TCA cycle flux, consistent with exhausting critical metabolites (PEP, CIT, FUM and α-KG), indicative of lung injury-associated energy deficiency. While no coordinated substrate-product variations were observed, we identify AMPK as a potential regulator of both glycolysis and TCA pathways. Typically, AMPK enhances pyruvate dehydrogenase (PDH) activity (via PDHA1 phosphorylation) to sustain pyruvate-to-acetyl-CoA conversion [36], while also promoting oxidative phosphorylation to regenerate TCA intermediates (e.g., FUM) and restore ATP production [37]. Furthermore, AMPK may alleviate sepsis-induced glycolytic suppression, maintaining PEP and CIT generation. This metabolic shift toward oxidative phosphorylation aligns with known benefits in SALI. Our findings highlight the central role of AMPK in SPD’s effects against SALI. Similarly, previous studies have indicated that polyamines, including spermidine, can influence cellular metabolism through other AMPK-dependent pathways. For instance, SPD has been shown to enhance mitochondrial superoxide production, which subsequently activates AMPK and promotes anti-inflammatory responses through Hif-1α stabilization and autophagy induction [38]. Additionally, SPD administration ameliorates hepatic steatosis by regulating key lipid-metabolizing enzymes in an AMPK-dependent manner, suppressing lipogenic enzymes while promoting lipid oxidation [39]. These findings collectively suggest that SPD operates within an integrated regulatory network where mitochondrial function, metabolic enzyme activity, and autophagy processes converge through AMPK signaling. While our current evidence supports AMPK as the central mediator, we cannot exclude the possibility that SPD might additionally fine-tune metabolic outcomes through direct interactions with metabolic enzymes or mitochondrial components or even certain inherent metabolites within the local microenvironment [40]. Such potential multi-level regulation would further strengthen SPD’s capacity to restore metabolic homeostasis under pathological conditions. Sepsis impairs mitochondrial electron transport chain (ETC) function and ATP synthesis, while Transient Receptor Potential Vanilloid 4 (TRPV4)-mediated Facilitative glucose transporter (GLUT1) regulation in macrophages influences glucose uptake and glycolysis, impacting lung protection [41]. Although DEX similarly activates AMPK to suppress necroptosis (via RIPK/MLKL downregulation), its clinical use is limited by side effects. In contrast, SPD emerges as a promising agent for SALI intervention by both enhancing anti-inflammatory effects and restoring metabolic homeostasis through AMPK activation. SPD has been revealed elsewhere to effectively suppress RIPK1-mediated cell death and ameliorates diabetic phenotypes in vivo [6]. However, our findings indicate that the suppression of RIPK1 by SPD is at least partially AMPK-dependent in the alleviation of SALI. Within both in vivo and in vitro experiments, AMPK inhibitions by Compound C exhibit to reduce SPD’s effects on RIPK1 inhibition, emphasizing the role of AMPK during the regulation of necroptosis. While we cannot exclude the possibility of direct RIPK1 inhibition by SPD, our study highlights that AMPK activation-mediated metabolism modulations are pivotal for the anti-necroptosis effect of SPD. Several limitations warrant consideration in the current work. Firstly, although SPD exhibits both anti-inflammatory and anti-necroptosis properties, our investigation exclusively considers its direct modulation of the AMPK/RIPK1 pathways in SALI. The potential synergistic or antagonistic effects of the downstream metabolic products of SPD remain uncharacterized. Secondly, our analysis is primarily based on the samplings obtained at the early hyperinflammatory phase of SALI, the dynamic nature of sepsis pathophysiology necessitates a long-term evaluation of SPD’s stage-dependent effects. Thirdly, even though BMDMs provide a well-validated model due to their homogeneity and similar responses of pro-inflammatory lung macrophages induced by LPS stimulation [42–44], it is important to acknowledge that this model may not fully capture the complex phenotypic diversity and tissue-specific functions of resident lung macrophages like alveolar macrophages within the intact lung microenvironment. Finally, the prophylactic administration of SPD in vivo, though methodologically necessary to avoid CLP-associated confounders, may not directly translate to clinical treatment scenarios. To further demonstrate the value of SPD in the complementary therapy to SALI, relevant clinical validations in patients with sepsis will be conducted in our future study. Conclusion This study demonstrates that SPD protects against SALI through AMPK-mediated attenuation of necroptotic pathways. Importantly, the current work provides evidence that SPD ameliorates SALI by restoring sepsis-induced disturbances in energy metabolism, including TCA cycle and glycolytic dysfunction. These findings position SPD as a promising nutraceutical candidate for complementary sepsis therapy, potentially offering novel therapeutic strategies for clinical management. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 (DOCX 24.3 MB) Acknowledgements We thank Dr. Lei Di for his help in the study design and validation of the findings. We also appreciate the help during in vivo and in vitro experiments from Ms. Liuliu Lu and Mr. Zhenchen Lu. Abbreviations Spermidine Dexamethasone Compound C Sepsis-induced acute lung injury Specific pathogen free Adenosine AMP-activated protein kinase Receptor-interacting protein kinase 1 Mixed-lineage kinase domain-like Cecal ligation and puncture Bronchoalveolar lavage fluid Bone marrow-derived macrophages Lipopolysaccharide Interleukin 6 Interleukin 1β Tumor necrosis factor α Tricarboxylic acid cycle Pyruvate dehydrogenase Electron transport chain Transient receptor potential vanilloid 4 Facilitative glucose transporter Author Contributions Bingqing Ye: Writing – original draft, Investigation, Data curation. Yuan Jin: Validation, Software, Methodology. Shansong Hu: Investigation, Formal analysis, Data curation. Yiwei Shao: Investigation, Formal analysis, Software. Qiaoyu Yang: Visualization, Investigation, Formal analysis. Han Wu: Validation, Software, Investigation. Funding Statement This work was supported by the Natural Science Research Project of the Anhui Educational Committee (2023AH050591), and the funding of discipline development of Anhui Medical University (2020xkjT019). Data Availability Involved original data which are not present in the manuscript, including the original images of immunoblots have been uploaded to an open-access document with the DOI: 10.6084/m9.figshare. Declarations Ethical Approval All experiments involving animal subjects were conducted in strict accordance with the guidelines approved by the Animal Care Committee of Anhui Medical University (LLSC20240853). Competing Interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Bingqing Ye and Yuan Jin contributed equally. References Associated Data Supplementary Materials Supplementary Material 1 (DOCX 24.3 MB) Data Availability Statement Involved original data which are not present in the manuscript, including the original images of immunoblots have been uploaded to an open-access document with the DOI: 10.6084/m9.figshare.